Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
22 Maio 2023 - 11:03PM
Business Wire
Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology
company, today announced the pricing of an upsized underwritten
public offering of 12,500,000 shares of its common stock at a
public offering price of $28.00 per share, before deducting
underwriting discounts and commissions. In addition, Guardant
Health has granted the underwriters a 30-day option to purchase up
to an additional 1,875,000 shares of common stock at the public
offering price, less underwriting discounts and commissions. The
gross proceeds from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
Guardant Health, are expected to be $350.0 million, excluding any
exercise of the underwriters’ option to purchase additional shares.
The offering is expected to close on or about May 25, 2023, subject
to the satisfaction of customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen and SVB
Securities are acting as joint book-running managers for the
offering.
The shares of common stock are being offered by Guardant Health
pursuant to an automatic shelf registration statement on Form S-3
that was previously filed with the U.S. Securities and Exchange
Commission, or the SEC, and automatically became effective upon
filing. A preliminary prospectus supplement and accompanying
prospectus relating to and describing the terms of the offering has
been filed with the SEC and is available on the SEC’s website at
www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained by contacting:
J.P. Morgan Securities LLC c/o Broadridge Financial Solutions
1155 Long Island Avenue, Edgewood, NY 11717 Telephone: (866)
803-9204, or email: prospectus-eq_fi@jpmorganchase.com;
Goldman Sachs & Co. LLC Attention: Prospectus Department 200
West Street, New York, NY 10282 Telephone: (866) 471-2526, or
email: prospectus-ny@ny.email.gs.com;
Cowen and Company, LLC 599 Lexington Avenue, New York, NY 10022
Telephone: (833) 297-2926, or email: Prospectus_ECM@cowen.com;
SVB Securities LLC Attention: Syndicate Department 53 State
Street, 40th Floor, Boston, MA 02109 Telephone: (800) 808-7525,
ext. 6105, or email: syndicate@svbsecurities.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced-stage cancer, and Guardant
Reveal™ for early-stage cancer. The Guardant Health screening
portfolio, including the commercially launched Shield™ test, aims
to address the needs of individuals eligible for cancer
screening.
Forward Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation statements regarding the
expected closing of the public offering are forward-looking
statements reflecting the current beliefs and expectations of
Guardant Health’s management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements represent Guardant Health’s current
expectations regarding future events and are subject to known and
unknown risks and uncertainties that could cause actual results to
differ materially from those implied by the forward-looking
statements. Among those risks and uncertainties are market
conditions, including market interest rates, the trading price and
volatility of Guardant Health’s common stock, and risks relating to
Guardant Health’s business, including those risks described in
periodic reports that Guardant Health files from time to time with
the SEC, as well as the preliminary prospectus supplement and
accompanying prospectus relating to the offering. The
forward-looking statements included in this press release speak
only as of the date of this press release, and Guardant Health does
not undertake to update the statements included in this press
release for subsequent developments, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230522005761/en/
Investor Contact: investors@guardanthealth.com Media
Contact: press@guardanthealth.com
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024